Loading clinical trials...

Monkeypox, Biology, Outcome, Transmission and Epidemiology -Prospective Follow-up of High-risk Contacts | Clinical Trials | Clareo Health

COMPLETED

Monkeypox, Biology, Outcome, Transmission and Epidemiology -Prospective Follow-up of High-risk Contacts

Mpox, Biology, Outcome, Transmission and Epidemiology - Prospective Follow-up of High-risk Contacts

NCT06136117•Institute of Tropical Medicine, Belgium

View on ClinicalTrials.gov

Summary

With the MBOTE-CONTACT study, a detailed follow-up study of high-risk contacts of mpox patients will be done. The MBOTE-CONTACT study will be nested in the NIH-Funded PALM-007 clinical trial (NCT05559099) and the MBOTE project on mpox transmission. The study will take place in Maniema Province, Democratic Republic of Congo (DRC). Participants will be recruited among high-risk contacts of mpox patients included in the PALM-007 trial. Consenting contacts will be either followed daily at the central study site or visited weekly by an outreach team in the community. They will be examined daily for signs and symptoms and asked to provide daily saliva and weekly blood samples for polymerase chain reaction (PCR) and/or serology. If participants develop mpox, they are offered treatment and enrollment in the PALM-007 trial.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•▪ Be a high-risk contact of a laboratory-confirmed mpox case, with high-risk defined as having at least one the following types of exposure:
•living in the same household as an mpox patient
•having had sexual contact or intercourse with an mpox patient
•sleeping in the same room as an mpox patient
•sharing a meal with an mpox patient
•children: having played together
•* Last exposure to the mpox index case of less than 14 days ago
•* Patients of any age and gender (children aged \< 10 years are excluded from venous blood sampling)
•* Patient or culturally acceptable representative is willing and able to give informed consent for participation in the study

Exclusion Criteria

•Having previously been diagnosed with mpox in the last 3 months
•Inability or unwillingness to comply with the proposed follow-up schedule

Locations (1)

Tunda

Tunda, Maniema Province, Democratic Republic of the Congo

Key Dates

Start Date

May 22, 2023

Primary Completion Date

October 1, 2024

Completion Date

October 1, 2024

Last Updated

May 7, 2025

Enrollment

257

ACTUAL participants

Conditions

Mpox

A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

NCT07379580

Mpox (Monkeypox)Smallpox+1 more

View study

RECRUITINGNA

Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks

NCT06887556

Mpox

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 7, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Monkeypox, Biology, Outcome, Transmission and Epidemiology -Prospective Follow-up of High-risk Contacts

Inclusion Criteria

Exclusion Criteria

A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa

Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks

Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part2)

Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part3)

A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age